Debut Diamonds Inc. Stock Canadian Securities Exchange

Equities

DDI

CA24276X1042

Delayed Canadian Securities Exchange 5-day change 1st Jan Change
- CAD -.--% Intraday chart for Debut Diamonds Inc. -.--% +48.57%
Dynamic Chart
Made Therapeutics, Inc. completed the acquisition of Debut Diamonds Inc. from Jason I. Goldman Professional Corporation, Marc Lustig, Steven Mintz, Camille Rabay, Rajiv Bhatia,Greg Wilson and others in a reverse merger transaction. CI
Debut Diamonds Inc. Reports Earnings Results for the Third Quarter Ended January 31, 2021 CI
Debut Diamonds Inc. Appoints Yazeed Esnan to the Current Board of Directors CI
Made Therapeutics, Inc. entered into letter agreement to acquire Debut Diamonds Inc. from Jason I. Goldman Professional Corporation, Marc Lustig, Steven Mintz, Camille Rabay, Rajiv Bhatia,Greg Wilson and others in a reverse merger transaction. CI
Debut Diamonds Inc. Announces Earnings Results for the Second Quarter Ended October 31, 2020 CI
Rajiv Bhatia entered into a share purchase agreement to acquire 11.41% interest in Debut Diamonds Inc. from Marc Lustig for CAD 0.08 million. CI
Debut Diamonds Inc. Reports Earnings Results for the First Quarter Ended July 31, 2020 CI
Debut Diamonds Inc. Reports Earnings Results for the Full Year Ended April 30, 2020 CI
Inolife R&D Inc. cancelled the acquisition of Debut Diamonds Inc. in a reverse merger transaction. CI
Debut Diamonds Inc. Reports Earnings Results for the Third Quarter Ended January 31, 2020 CI
Inolife R&D Inc. entered into a binding memorandum of agreement to acquire Debut Diamonds Inc. in a reverse merger transaction. CI
Debut Diamonds Inc. Announces the Executive Changes CI
KWG Resources Inc. acquired All the mining claims of Debut Diamonds Inc. for CAD 1200. CI
Debut Diamonds Inc. Reports Earnings Results for the Second Quarter Ended October 31, 2019 CI
Debut Diamonds Inc. Reports Earnings Results for the Full Year Ended April 30, 2019 CI
More news
Wesana Health Holdings Inc, formerly Debut Diamonds Inc. (Debut), is a Canada-based life science company. The Company is engaged in development and delivery of psychedelic and naturally sourced therapies to treat traumatic brain injury (TBI) and related conditions. It develops evidence-based formulations and protocols for patients to overcome neurological, psychological and mental health ailments caused by trauma.
Sector
-
More about the company